Cargando…
Pre-Clinical Characterization of Dacomitinib (PF-00299804), an Irreversible Pan-ErbB Inhibitor, Combined with Ionizing Radiation for Head and Neck Squamous Cell Carcinoma
Epidermal growth factor receptor (EGFR) is over-expressed in nearly all cases of squamous cell carcinoma of the head and neck (SCCHN), and is an important driver of disease progression. EGFR targeted therapies have demonstrated clinical benefit for SCCHN treatment. In this report, we investigated th...
Autores principales: | Williams, Justin P., Kim, Inki, Ito, Emma, Shi, Wei, Yue, Shijun, Siu, Lillian L., Waldron, John, O'Sullivan, Brian, Yip, Kenneth W., Liu, Fei-Fei |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4031184/ https://www.ncbi.nlm.nih.gov/pubmed/24853121 http://dx.doi.org/10.1371/journal.pone.0098557 |
Ejemplares similares
-
Dacomitinib, an Irreversible Pan-ErbB Inhibitor Significantly Abrogates Growth in Head and Neck Cancer Models That Exhibit Low Response to Cetuximab
por: Ather, Ferdows, et al.
Publicado: (2013) -
A phase 2 trial of dacomitinib (PF‐00299804), an oral, irreversible pan‐HER (human epidermal growth factor receptor) inhibitor, in patients with advanced non–small cell lung cancer after failure of prior chemotherapy and erlotinib
por: Reckamp, Karen L., et al.
Publicado: (2014) -
Phase I and pharmacokinetic study of dacomitinib (PF-00299804), an oral irreversible, small molecule inhibitor of human epidermal growth factor receptor-1, -2, and -4 tyrosine kinases, in Japanese patients with advanced solid tumors
por: Takahashi, Toshiaki, et al.
Publicado: (2012) -
Dacomitinib, a pan-inhibitor of ErbB receptors, suppresses growth and invasive capacity of chemoresistant ovarian carcinoma cells
por: Momeny, Majid, et al.
Publicado: (2017) -
A Pre-Clinical Assessment of the Pan-ERBB Inhibitor Dacomitinib in Pediatric and Adult Brain Tumors
por: Endersby, Raelene, et al.
Publicado: (2018)